LVTX
Closed
Lava Therapeutics Nv
1.32
0.00 (0.00%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.32
Day's Range: 1.31 - 1.35
Send
sign up or login to leave a comment!
When Written:
1.43
LAVA Therapeutics NV is a clinical-stage biotechnology company that is focused on developing novel bispecific antibodies to treat cancer. The company's lead product candidate, LAVA-051, is a bispecific antibody that targets both CD123 and CD3, two proteins that are overexpressed on cancer cells and T cells, respectively. LAVA-051 is currently in Phase 1/2a clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
LAVA Therapeutics was founded in 2016 and is headquartered in Utrecht, the Netherlands. The company has a team of experienced scientists and executives who have expertise in antibody engineering, immunology, and oncology. LAVA Therapeutics has also established partnerships with several leading pharmaceutical companies, including Janssen Biotech and Sanofi.
In addition to LAVA-051, the company is also developing a pipeline of other bispecific antibodies that target different cancer antigens and immune cells. LAVA Therapeutics aims to leverage its proprietary technology platform to develop innovative cancer therapies that can improve patient outcomes and quality of life.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
LAVA Therapeutics was founded in 2016 and is headquartered in Utrecht, the Netherlands. The company has a team of experienced scientists and executives who have expertise in antibody engineering, immunology, and oncology. LAVA Therapeutics has also established partnerships with several leading pharmaceutical companies, including Janssen Biotech and Sanofi.
In addition to LAVA-051, the company is also developing a pipeline of other bispecific antibodies that target different cancer antigens and immune cells. LAVA Therapeutics aims to leverage its proprietary technology platform to develop innovative cancer therapies that can improve patient outcomes and quality of life.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








